Navigation Links
Irvine Pharmaceutical Services Enhances Staff, Prepares for Innovative Expansion
Date:10/29/2008

IRVINE, Calif., Oct. 29 /PRNewswire/ -- Irvine Pharmaceutical Services, Inc., announced today that as part of its ongoing efforts to identify and meet current and future industry demands, the company has promoted Aryo Nikopour to Vice President of Scientific and Technical Services and added to its staff Chief Operating Officer Greg McParland. These changes come at an opportune time in the company's growth as it gears up to launch its new subsidiary, Avrio Biopharmaceuticals, in January 2009.

After five years at Irvine and with a cumulative 20-plus years experience in the pharmaceutical industry, Aryo Nikopour offers to his new position a solid understanding and knowledge of the company as well as pharmaceutical development. His previous positions at highly reputable organizations such as PPD, Alpharma (Actavis), Solvay Pharmaceuticals and Solvay Animal Health, to name a few, has helped develop his expertise in a range of areas, including chromatographic method development and validation, Extractables/Leachables studies, and implementation of new technologies and capabilities such as Inhalation/Nasal, Biopharmaceutical and Structural Chemistry. Nikopour also has strong experience in scientific staff management, quality control, stability testing and regulatory requirements.

Greg McParland brings to Irvine more than 30 years of experience in the pharmaceutical and chemical industries. Prior to joining Irvine, McParland was Chief Executive Officer of Girindus America Inc., a member of Solvay Organics. There, McParland lead the R&D focused company through a major transition to become a commercial operation focused on small molecule and oligonucleotide active pharmaceutical ingredients. His additional leadership experience at companies such as Cambrex Corporation, Altergy Systems, NextPharma and Aerojet Fine Chemicals, in the areas of operations, sales and marketing, strategic planning, process optimization, and mergers and acquisitions, will be invaluable to both Irvine Pharmaceuticals and its new company, Avrio Biopharmaceuticals.

"We are looking forward to continued growth under the leadership of Aryo Nikopour and Greg McParland," said Assad J. Kazeminy, CEO and Founder of Irvine Pharmaceutical Services. "I am confident they will lead us to even greater success as we expand and work to provide ever improving services to our clients."

Since early 2007, Irvine Pharmaceutical Services, Inc., has experienced extensive growth, and has made significant upgrades in its lab equipment and infrastructure. You can meet Irvine staff and learn more about the company at the AAPS Annual Meeting, booth 1707.

About Irvine

Irvine Pharmaceutical Services, Inc. is a fully integrated services provider that works with pharmaceutical, biotechnology and medical device companies through all phases of research and development. Founded in 1988 and committed to expansion and services that benefit its clients' priorities directly, Irvine is a fully cGMP compliant contract testing laboratory located in Irvine, CA. Visit http://www.irvinepharma.com or call (877) 445-6554.


'/>"/>
SOURCE Irvine Pharmaceutical Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hoag Hospital Announces Agreement to Open Irvine Campus
2. Lucas Group to Host Military Hiring Conferences in Washington, DC; Irvine, CA and Dallas, TX
3. UC Irvine to lead statewide program on green materials research
4. UC Irvine researchers present latest findings at emergency medicine forum
5. UC-Irvine scientists present groundbreaking research at Society for Neuroscience conference
6. Watson Pharmaceuticals Reports Third Quarter 2008 Results
7. Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
8. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
11. WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/28/2016)... ... ... of the city where’s it’s easy to spot the neon lights of chains serving fast ... diners with a taste for real food. , On May 13, the Best ... urban casual restaurant focusing on dishes made by hand with wholesome, organic ingredients that are ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Hutchison China ... focused on the highly lucrative global oncology and ... of potential first-in-class or best-in-class tyrosine kinase inhibitor ... with strategic partners. HCM,s profitable Chinese healthcare business ... We expect progress of the mid-to-late-stage pipeline during ...
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology: